Why moving from Big Pharma to a midsize specialty firm can boost impact and leadership

Thomas Kolaras, formerly with large pharmaceutical companies, now works at SERB Pharmaceuticals and reflects on the benefits and constraints of big‑pharma environments. He highlights the rigorous processes, extensive training, and scale that large firms provide, while noting the limits they can impose on agility.

He describes a recent incident where his supply team swiftly transferred a life‑saving product between hospitals, without lengthy reviews or escalations. The quick, real‑time response illustrated how impact at a midsize, patient‑focused company is measured by immediacy rather than scale.

Kolaras concludes that moving closer to the patient in a specialty firm fosters sharper thinking, leadership opportunities, and the ability to act decisively, complementing the strengths he gained from his big‑pharma background.